PMC9082665_01
Main clinical and biologic findings and therapeutic interventions in three patients treated with tofacitinib. The Figures illustrated Case 1 (A), Case 2 (B), and Case 3 (C), respectively. CRP and Hb referred to the left Y axis, SF referred to the right Y axis. CRP, C-reaction protein; Hb, hemoglobin; SF, serum ferritin; Tofa, tofacitinib (mg/day); Pred, prednisone (mg/day); Dx, dexamethasone; MDS-RS, Myelodysplastic Syndrome with ring sideroblasts.
fmed-09-895965-g001.jpg
PMC9082665_03_fmed-09-895965-g001.jpg
F1
A month later, his hemoglobin level reduced from 101 g/L to 59 g/L despite of resuming prednisone and tofacitinib treatments (Figure 1C). A second BM examination was performed 13 months after the first biopsy.
PMC9082665_02
Main clinical and biologic findings and therapeutic interventions in three patients treated with tofacitinib. The Figures illustrated Case 1 (A), Case 2 (B), and Case 3 (C), respectively. CRP and Hb referred to the left Y axis, SF referred to the right Y axis. CRP, C-reaction protein; Hb, hemoglobin; SF, serum ferritin; Tofa, tofacitinib (mg/day); Pred, prednisone (mg/day); Dx, dexamethasone; MDS-RS, Myelodysplastic Syndrome with ring sideroblasts.
fmed-09-895965-g001.jpg
PMC9082665_03_fmed-09-895965-g001.jpg
F1
A month later, his hemoglobin level reduced from 101 g/L to 59 g/L despite of resuming prednisone and tofacitinib treatments (Figure 1C). A second BM examination was performed 13 months after the first biopsy.
PMC9082665_03
Main clinical and biologic findings and therapeutic interventions in three patients treated with tofacitinib. The Figures illustrated Case 1 (A), Case 2 (B), and Case 3 (C), respectively. CRP and Hb referred to the left Y axis, SF referred to the right Y axis. CRP, C-reaction protein; Hb, hemoglobin; SF, serum ferritin; Tofa, tofacitinib (mg/day); Pred, prednisone (mg/day); Dx, dexamethasone; MDS-RS, Myelodysplastic Syndrome with ring sideroblasts.
fmed-09-895965-g001.jpg
PMC9082665_03_fmed-09-895965-g001.jpg
F1
A month later, his hemoglobin level reduced from 101 g/L to 59 g/L despite of resuming prednisone and tofacitinib treatments (Figure 1C). A second BM examination was performed 13 months after the first biopsy.
PMC9082665_04
PMC9082665_05
Representative gastrointestinal involvement in our cases. Typical endoscopic findings showed multiple ulcers of terminal ileum (A) and the lower jejunum (B). Pathology suggested multiple shallow ulcers in the small intestinal mucosa (C).
fmed-09-895965-g002.jpg
PMC9082665_05_fmed-09-895965-g002.jpg
F2
Endoscopy was performed and showed multiple oval ulcers in lower jejunum and terminal ileum (Figures 2A,B). Biopsy revealed eosinophil infiltration in mucosa and submucosa and no epithelioid granuloma was found (Figure 2C).
PMC9082665_06